New Pancreatic Cancer Drug Combo Begins US Trial

Patients with pancreatic cancer now have a new reason for hope as doctors begin testing a powerful drug combination that early studies show could outperform existing treatments.

The RASolute 309 trial started dosing patients in October at Moffitt Cancer Center in Tampa, Florida, with plans to expand globally and enroll 400 adults by 2029. The study tests Rasonque, a pancreatic cancer drug approved in August, alongside an experimental medication called zoldonrasib.

Both drugs target a specific genetic mutation called RAS G12D, found in many pancreatic tumors. This mutation causes a protein that normally controls cell growth to go haywire, fueling cancer's spread throughout the body.

The trial focuses on patients with metastatic pancreatic adenocarcinoma, the disease's most common form, where cancer has already spread beyond the pancreas. Participants must not have received prior treatment for their metastatic disease, giving researchers the clearest picture of how well the combination works.

What makes this approach special is how the two drugs work together. Rasonque blocks multiple versions of the faulty RAS protein, while zoldonrasib specifically targets the G12D mutation. Revolution Medicines, the company developing both treatments, discovered this tag team approach might deliver a one two punch cancer cells can't escape.

"RAS G12D is the most common RAS variant in PDAC," said Dr. Alan Sandler, Revolution's chief development officer. The company's preclinical studies showed the combination achieved deeper and longer lasting suppression of cancer signaling than either drug alone.

Initial human trials back up that promise. Patients with previously treated metastatic pancreatic cancer showed compelling responses to the combination, and side effects remained manageable.

The Bright Side

Pancreatic cancer has long been one of the hardest cancers to treat, making any progress feel monumental. This trial represents a shift toward precision medicine, where treatments target the exact genetic problems driving each patient's cancer rather than using a one size fits all approach.

The speed of progress matters too. Rasonque gained approval just two months before this trial began dosing patients, showing how quickly promising treatments can move from approval to expanded testing. With recruitment already underway and multiple testing sites planned worldwide, researchers are moving fast to get answers.

For the thousands of Americans diagnosed with pancreatic cancer each year, having more targeted options could mean more time with loved ones and better quality of life during treatment.

This trial runs through 2029, but every patient enrolled brings science one step closer to turning pancreatic cancer from a devastating diagnosis into a manageable disease.